Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Paul B. Harvilla, Ninkka Tamot, Adam Zwolak, Jason Ho, Matthew D. Truppo, Rajitha Doddareddy, Tong-Yuan Yang, M. Jack Borrok, Ian White, Chowdhury Partha, Qun Jiao, Rajkumar Ganesan, Brian Geist
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The global health crisis and economic tolls of COVID-19 necessitate a panoply of strategies to treat SARS-CoV-2 infection. To date, few treatment options exist, although neutralizing antibodies against the spike glycoprotein have proven to be effecti
Autor:
Bo R. Rueda, Jillian M. Prendergast, David A. Eavarone, Jeff Behrens, Julie DeSander, Joan Wicks, Dane A. Brady, Mai Zhang, Darius Ghaderi, Ana Paula Galvao da Silva
Publikováno v:
mAbs
Targeted therapeutics that can differentiate between normal and malignant tumor cells represent the ideal standard for the development of a successful anti-cancer strategy. The Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s) i
Publikováno v:
mAbs
Secukinumab is a human monoclonal antibody that selectively targets interleukin-17A and has been demonstrated to be highly efficacious in the treatment of moderate to severe plaque psoriasis, starting at early time points, with a sustained effect and
Autor:
Tiansheng Li, Yang Liu, Yanchun Ma, Meng Li, Lina Sun, Mifang Liang, Chuan Li, Li Chen, Lei Wang, Jisu Li, Shuping Tong, Wei Wang, Youhua Xie, Yumei Wen
Publikováno v:
mAbs. 8:468-477
Hepatitis B virus (HBV) produces large (L), middle (M), and small (S) envelope proteins, alternatively referred to as hepatitis B surface antigen (HBsAg). Currently, yeast-derived S protein serves as the preventive vaccine, while hepatitis B immune g
Autor:
Sahana Bose, Dominic J. Ambrosi, Tariq Ghayur, Rajesh V. Kamath, Chung-Ming Hsieh, Susan E. Lacy, Donna Conlon, Chengbin Wu, Edit Tarcsa, Ravi Chari, Renee Miller
Publikováno v:
mAbs
Interleukin-1 (IL-1) cytokines such as IL-1α, IL-1β, and IL-1Ra contribute to immune regulation and inflammatory processes by exerting a wide range of cellular responses, including expression of cytokines and chemokines, matrix metalloproteinases,
Autor:
Yunwei Wei, Valerie R. Wiersma, Marloes J. M. Gooden, Wijnand Helfrich, Djoke Hendriks, Hans W. Nijman, Douwe F. Samplonius, Jin Zhou, Maartje C.A. Wouters, Marco de Bruyn, Ce Shi, Edwin Bremer
Publikováno v:
mAbs, 7(2), 321-330
The therapeutic effect of anti-cancer monoclonal antibodies stems from their capacity to opsonize targeted cancer cells with subsequent phagocytic removal, induction of antibody-dependent cell-mediated cytotoxicity (ADCC) or induction of complement-m
Autor:
Ka-Wai Cheung, Minghui An, Xian Tang, Allen Ka Loon Cheung, Zhiwei Wu, Xin Yuan Guan, Jia Guo, Kenji Nishiura, Jie Peng, Xilin Wu, Li Liu, Jingying Zhou, Lin Cheng, Zhiwei Chen, Hui Wang, Hang Ying Tang
Publikováno v:
mAbs. 7:620-629
We recently reported the identification of Δ42PD1, a novel alternatively spliced isoform of human PD1 that induces the production of pro-inflammatory cytokines from human peripheral blood mononuclear cells and enhances HIV-specific CD8(+) T cell imm
Autor:
Shui-On Leung, Guang Yu Wang, Benny Ka-Wa Cheung, K.F. Lee, Qi Zhao, Wing-Tai Cheung, Jun Zhi Wang, Kai Gao
Publikováno v:
mAbs. 7:66-76
SM03, a chimeric antibody that targets the B-cell restricted antigen CD22, is currently being clinically evaluated for the treatment of lymphomas and other autoimmune diseases in China. SM03 binding to surface CD22 leads to rapid internalization, mak
Autor:
Elizabeth England, Trevor Wilkinson, Sarah Welsted, Jayesh B. Majithiya, Claire Dobson, Dominic J. Corkill, E. Suzanne Cohen, Natalie J. Tigue, Tristan J. Vaughan, Matthew J. Robinson, Kevin Minton, Jennifer L. Percival-Alwyn, Benjamin Kemp, Maria Groves, Laura Rapley, Nicola H.E. Davis, Grant R McCarthy
Publikováno v:
mAbs
Immunization of mice or rats with a "non-self" protein is a commonly used method to obtain monoclonal antibodies, and relies on the immune system's ability to recognize the immunogen as foreign. Immunization of an antigen with 100% identity to the en
Publikováno v:
mAbs
This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an anti-methamphetamine monoclonal antibody, in healthy volunteers. Single, escalating doses of ch-mAb7F9 over the range of 0.2 to 20 mg/kg were administered to 42 subje